Globus Medical will announce its financial results for the third quarter ended September 30, 2026, after the market close on November 5, 2026. The musculoskeletal technology company plans to host a conference call to discuss performance with the investment community immediately following the release.

Conference Call Details

The teleconference is scheduled for 4:30 pm Eastern Time on the same day as the earnings release. Participants may access the live webcast via the Investors page of the Globus Medical website. For telephone participation, registrants must sign up in advance to receive a confirmation email containing the dial-in number, unique passcode, and registrant ID.

An audio archive of the call will be available on the Investors page after the event concludes. The full press release will also be accessible on the company’s investor relations website.

About Globus Medical

Globus Medical is a global musculoskeletal technology company focused on addressing unmet clinical needs in spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. The company emphasizes innovation, education, and clinical support across its product lines.

Globus Medical reported second-quarter fiscal year 2026 revenue of $789.6 million, a 6% increase year-over-year. Excluding the Nevro acquisition, base business revenue grew 9%. Non-GAAP earnings per share rose 56% to $1.34.

The company achieved a quarterly record for fully diluted non-GAAP EPS, driven by adjusted EBITDA margin expansion to 35.4% from 28% in the prior-year quarter. U.S. Spine revenue grew 7%, while International Spine sales increased 14%. The company repurchased $136 million worth of shares during the period.

Segment Performance and Growth Drivers

Musculoskeletal revenue reached $763.5 million, growing 8% year-over-year. The growth was led by strong procedural volumes in the U.S. and international markets. Trauma revenue surged 31% year-over-year as supply constraints eased.

International revenue totaled $170.5 million, an 18% increase as reported. Double-digit growth was recorded across EMEA, Latin America, and APAC regions. The company highlighted deeper market penetration and improved inventory availability as key factors supporting international expansion.

Margin Expansion and Cost Discipline

Adjusted gross profit margin improved by 200 basis points to 69.4%, marking the seventh consecutive quarter of margin expansion. Management attributed this improvement to fixed-cost leverage, favorable sales mix, and synergy execution from manufacturing and supply chain initiatives.

SG&A expenses decreased to 36.3% of sales from 40.7% in the prior-year quarter. This reduction reflects lower employee-related costs from synergy actions and timing benefits on employee benefit claims, partially offset by higher sales compensation due to increased volume.

Strategic Initiatives and Capital Allocation

The company launched three new products during the quarter, including two trauma devices and one spine product. Over 60 organic development projects are currently in progress. The acquisition of Nevro aims to expand the addressable market into pain management, with integration efforts focused on restoring trial volumes by late Q4FY26.

Capital allocation priorities include internal investment in product development and share repurchases. Since September 2023, Globus Medical has invested $747 million in share buybacks, representing over 50% of free cash flow generation in that period.

What the Numbers Show

A divergence exists between top-line growth and bottom-line acceleration. While revenue grew 6%, non-GAAP EPS increased 56%, highlighting significant operating leverage. Adjusted EBITDA dollars grew 34% against a 6% revenue increase, indicating that margin expansion is outpacing volume growth. Additionally, the shift toward flexible leasing models for enabling technologies caused a 26% decline in that segment's reported revenue, yet unit deployments grew 25% year-over-year, suggesting a strategic transition rather than a demand loss.

Guidance Update

For fiscal year 2026, Globus Medical reaffirmed revenue guidance of $3.18 billion to $3.22 billion, implying growth of 8.2% to 9.6%. Non-GAAP fully diluted EPS guidance was raised to $4.95 to $5.05, up from the previous range of $4.70 to $4.80. This revision reflects stronger-than-expected margin performance in the first half of the year.